US-based clinical-stage biopharmaceutical company Dragonfly Therapeutics, Inc announced on Monday that it has named Dr Susan Altschuller as its new chief financial officer.
Dr Altschuller, a seasoned senior biopharma executive, has over two decades of strategic and financial leadership experience at pharmaceutical and biotechnology companies. She has served as the chief financial officer of Cerevel Therapeutics, chief financial officer of ImmunoGen, vice president and head of investor relations and later, head of enterprise finance at Alexion. Dr Altschuller has also worked as head of investor relations at Bioverativ and served in various positions in Biogen finance and as senior consultant at the Frankel Group.
Bill Haney, Dragonfly Therapeutics co-founder and CEO, said, 'We are delighted that Susan has joined Dragonfly. Her leadership growing successful biopharma companies comes at an exciting time as Dragonfly expands our clinical pipeline in autoimmune disease, oncology, and neuro-inflammatory disease. Susan's powerful combination of financial, clinical and development experience will help drive our mission to help patients by inventing and commercialising leading immune-engaging therapeutics.'
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Cantargia reports positive CAN10 trial data
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Scinai Immunotherapeutics reports positive results in psoriasis study
Johnson & Johnson acquires Yellow Jersey Therapeutics
Spine BioPharma, signs agreement with Ensol BioSciences
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
Delta-Fly Pharma initiates Phase III trial for lung cancer drug DFP-14323